Nevada Population Health Study to Offer Free 23andMe Genetic Tests to Community
September 15, 2016
Collaboration Aims to Change the Way State Thinks About Health
RENO, Nevada – Sept. 15, 2016 – Nevada-based Renown Health and the Desert Research Institute (DRI) are collaborating with 23andMe, a leading personal genetics company, to launch one of the first community-based population health studies in the U.S. that will combine health, population and genetic information with environmental data and return 23andMe genetic results to study participants.
Funded by the Renown Health Foundation and Nevada’s Knowledge Fund, this pilot study will offer community members the opportunity to volunteer for research and gain access to their individual genetic information at no cost.
23andMe’s Genotyping Services for Research platform will enable researchers to review genetic data and health-related survey responses from study participants. Combining genetic data with health and population data from Renown, as well as information from environmental databases, DRI scientists will analyze and model public health risks ranging from disease and illness, to the effects of air quality on the health of Nevadans.
“This collaboration addresses one of the fundamental tensions in medicine – which is more important nature or nurture?” explained Anthony Slonim, M.D., DrPH, Renown Health president and CEO. “Clearly, both are important and by combining Renown’s de-identified health data, such as 300,000 health histories that are five years or longer and patient population demographics, with other determinants, like social and environment, we can begin to better understand the health and healthcare needs of the people and communities we serve.”
The study is open to the first 5,000 northern Nevada residents that qualify.
“This is the ultimate example of population health in action in a community based setting,” Dr. Slonim added.
Each participant will receive 23andMe’s Personal Genome Service, including more than 65 personalized genetic reports on their health, traits and ancestry. 23andMe is the first and only direct-to-consumer genetics company to provide reports that meet FDA standards.
“We see this as an innovative approach to population health that will benefit Nevadans, and could serve as a model for other states,” said Andy Page, president of 23andMe. “It’s exciting to have Renown and DRI, leaders in healthcare and research, come together for a comprehensive study of this scale, and to see such a great application of our Genotyping Services for Research platform.”
Nevada Governor Brian Sandoval, who announced his participation as one of the first Nevada residents to complete 23andMe’s simple DNA test as part of this study, said this offers an unprecedented opportunity for residents of the Silver State.
“Nevada’s greatest resource is, and always has been, our people,” said Governor Sandoval. “Renown’s forward-thinking approach to community healthcare, combined with DRI’s data and environmental expertise, will create incredible potential for new scientific discoveries and encourage citizens just like myself to take a proactive role in self-care and ultimately change the way we think about our health moving forward.”
“This is a very proud moment for DRI and for Nevada, made possible because of Governor Sandoval’s vision for innovation through the Knowledge Fund,” added Dr. Robert Gagosian, DRI Acting President.
Researchers hope to build an infrastructure to apply the population health pilot to all approximately 2.8 million Nevada residents – doing so could enable researchers to build predictive models and to look for significant population health factors across demographic variables (gender, age, income, location); and distinct population health strata that consider community health, individual health, and chronic disease variables, as well as their interactions.
“We will begin to understand how environmental factors can help predict who may be at risk, allow for quicker diagnoses, and encourage the development of more precise treatments,” said Joseph Grzymski, Ph.D., AIC senior director and principal investigator of the study.
“That understanding, combined with the information we will deliver back to study participants, are the first steps toward a future where access to your personal health data will contribute to a higher overall quality of life for all Nevadans.”
For more information and to sign up for the study, visit www.partners.renown.org or call (775) 982-6914.
Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving a 17-county region comprised of northern Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 6,000. It comprises three acute care hospitals, a rehabilitation hospital, skilled nursing, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown has a long tradition of being the first in the region to successfully perform leading-edge medical procedures. For more information, visit www.renown.org.
Desert Research Institute (DRI), the nonprofit research arm of the Nevada System of Higher Education, is a world leader in environmental sciences through the application of knowledge and technologies to improve people’s lives throughout Nevada and the world. Supported by Nevada’s Knowledge Fund, the DRI Applied Innovation Center (AIC) aims to aid and improve the new, knowledge-based economy in Nevada by integrating DRI’s core areas of expertise in hydrologic, atmospheric, earth and ecosystem sciences with data analysis and informatics, visualization, modeling and simulation. More information about DRI’s Applied Innovation Center is available at www.dri.edu.
23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.